D
isease-associated fibrosis is a common, progressive sequel of multiple diseases as well as postoperative healing, often resulting in chronic morbidity (1) . Fibrosis is characterized by localized fibroblast proliferation and/ or elaboration, deposition, and accumulation of excess collagen in diverse organ systems and body tissues (2, 3) . The underlying inciting event to accelerated fibrosis is often varying degrees of tissue trauma. Although fibrosis is an efficient healing mechanism, it replaces native organ parenchyma, resulting in functional compromise. Disease symptoms often reflect ongoing pathology as well as underlying organ and/or tissue dysfunction as evidenced in cirrhosis, pulmonary fibrosis, cystic fibrosis, collagen vascular diseases, surgical scarring, and endometriosis (4) (5) (6) (7) (8) (9) (10) (11) .
We have previously demonstrated fibrotic progression associated with endometriosis-like lesions in an animal disease model. Endometriosis affects at least 10% of reproductive age women and is frequently associated with scarring (12, 13) . Endometriotic lesions are usually associated with perilesional scarring in early stage disease and more extensive fibrosis in advanced stages, resulting in a "frozen pelvis" with obliteration of pelvic and abdominal anatomy (14) . Fibrotic involvement of other organ systems expands disease symptoms to include gastrointestinal and genitourinary manifestations as well.
Postoperative fibrotic scarring as well as that observed in an array of chronic systemic diseases phenotypically resembles advanced endometriosis. Endometriosis is thus a medically relevant model for investigation of progressive fibrosis, a sequel that has even wider clinical significance extending to other chronic diseases and postoperative healing.
The Sp/KLF transcription factor Krüppel-like factor 11 (KLF11) is associated with several endocrine and female reproductive tract diseases such as diabetes, leiomyomata, endometriosis, and ovarian cancer (15) (16) (17) (18) . Notably, we have shown that the transcription factor is selectively diminished in endometriosis lesions compared with uterine (eutopic) endometrium from the same individual (18) . KLF11 is one of 24 Sp/KLF family transcription factors that are defined on the basis of their homologous C-terminal zinc finger DNA binding domains; the latter interact with specific promoter guanine-cytosine elements to regulate most expressed genes (19, 20) . In contrast, their unique N-termini recruit and bind distinct epigenetic cofactors that influence the direction of gene expression (21) .
In a Klf11 2/2 female, mouse endometriosis model, we determined that loss of Klf11 is associated disease progression and fibrosis (18) . We also determined that fibrosis in this model is due to loss of Klf11/histone deacetylase-mediated inhibition of the predominant scar tissue protein collagen 1a1 (Col1a1), which could be successfully targeted pharmacologically using a histone acetyl transferase inhibitor to prevent scarring (22) . Given the female predilection of chronic fibrotic medical diseases and high frequency of postoperative scarring, we hypothesized a role for sex steroids in the etiology of fibrosis. Our previous findings show that loss of Klf11 expression results in fibrotic progression via Col1a1 dysregulation; we investigate here the molecular regulation of Klf11 and its target Col1a1 in vitro by sex steroids as well as the resultant effect of such regulation on fibrosis in vivo. We use here a previously characterized peritoneal fibrosis model rather than the endometriosis model to comparatively evaluate sexually dimorphic responses in males and females (23) .
Materials and Methods

Animal experiments
All animal experiments were performed in accordance with the Guide for Care and Use of Laboratory Animals from the National Institutes of Health. These guidelines were incorporated into the current study protocol, which was approved by the Institutional Animal Care and Use Committee, at Mayo Clinic, Rochester, Minnesota.
Sterile peritonitis: induction and evaluation
Sterile peritonitis was induced in 8-week-old Klf11 2/2 male and female mice and control wild-type (wt) animals (n = 5 to 10 animals in each group). Mice in each group were injected using daily intraperitoneal 0.1% pharmaceutical chlorhexidine gluconate (C9394; Sigma): 0.015 mg/g in 15% ethanol in 13 phosphate-buffered saline (PBS). Total injection volume was 100 mL; control treatments comprised 15% ethanol vehicle only at a volume of 100 mL. Treatments were administered for 3 weeks. At the end of 3 weeks, necropsy was performed. Mice phenotype was evaluated objectively by at least two investigators who were blinded to the treatment condition, using a modified fibrosis score from a previously published fibrosis scores for murine endometriosis and intraperitoneal (IP) fibrosis (18) . This scoring system was modified from the previous endometriosis scoring system, as no peritoneal lesions were implanted in the current experimental design. Accordingly, modified fibrosis scores for our study could range from 9 to 88, with a score of 9 indicating no fibrosis seen.
Ovariectomy and sham surgery
Klf11
2/2 female mice and control wt animals (aged 8 weeks) underwent ovariectomy through a midline dorsal incision per published protocol (24) . Briefly, after being anesthetized, the lumbar dorsum was shaved and a midline dorsal incision made. The abdominal cavity was entered, and each ovary was individually exposed. The ovarian pedicle was clamped using hemostat pressure for 2 minutes, following which the ovary was removed using a scalpel; hemostasis was confirmed after unclamping the pedicle before initiating ovariectomy on the other side or closure of the incisions using a nonabsorbable suture. Control animals underwent sham surgery. During sham surgery, a similar incision was made and the mouse ovaries were identified bilaterally, grasped and examined, but not removed.
Sex steroid replacement
One week after surgery, the mice were initiated on sex steroid treatment or control injections. All sex steroids were dissolved in sesame oil and administered with a total injection volume of 50 mL in the thigh per previously published protocols (25, 26) . All injections were given daily for 4 weeks. Estradiol benzoate (ab145743; Cambridge) was prepared at a concentration of 0.1 mg/mL for a daily dose of 5 mg. Progesterone, 4-Pregnene-3, 20-dione (P0130; Sigma) was prepared at a concentration of 1 mg/mL for a daily dose of 0.05 mg. Dosing of estradiol and progesterone replacement were used to mimic the endogenous mouse exposure, as evidenced by induction of the estrus cycle (26). 5-a-Dihydrotestosterone (D-073; Cerilliant) was prepared at a concentration of 0.04 mg/mL for a daily dose of 2 mg. Control vehicle injections comprised 50 mL sesame oil. One week after initiation of hormone replacement or control injections, the animals were treated with IP injections of chlorhexidine gluconate or vehicle (15% ethanol in 13 (PBS). Necropsy was performed 3 weeks after chlorhexidine injection initiation.
Antiprogestin therapy
Like sex steroids, antiprogestin agents were dissolved in sesame oil and administered with a total injection volume of 50 mL in the thigh. Mifepristone (RU486) was prepared at a concentration of 6 mg/mL for a daily dose of 0.3 mg (27, 28) . Ulipristal was prepared at a concentration of 16 mg/mL and given to mice at a daily dose of 0.8 mg (29) . Control injections consisted of 50 mL sesame oil. One week after drug therapy initiation, sterile peritonitis was initiated in a fashion similar to that mentioned previously. Necropsy was performed 4 weeks after initiation of drug treatment, which corresponded to 3 weeks of IP chlorhexidine injections. Fibrosis scores were documented as mentioned previously. At least five mice were included in each group.
Orchiectomy and progesterone treatment
Klf11
2/2 male mice and control wt animals (aged 8 weeks) underwent orchiectomy per published protocol (24) . Briefly, after being anesthetized, the testes were brought into the scrotal sacs, incised, and removed. Control animals underwent sham surgery. During sham surgery, a similar incision was made and the mouse testes were identified bilaterally, grasped and examined, but not removed. Progesterone given to male mice was provided in the same concentration as the female mice as described earlier. One week after initiation of hormone replacement or control injections, the animals were treated with IP injections of chlorhexidine gluconate or 15% ethanol control as described previously. Necropsy was performed 3 weeks after chlorhexidine injection initiation.
Histochemistry
At necropsy, liver, peritoneum, and uterine samples were collected in formaldehyde. Slides were prepared by the Histology Core Laboratory in Mayo Clinic, Scottsdale, Arizona. Liver and uterus were examined longitudinally and the peritoneum was examined in cross section. Specimens were stained with Masson's trichrome, in which collagen appeared blue per laboratory protocol (18, 30, 31) . Images of Masson trichromestained sections were captured with a color image at 3100 magnification objective. Slides were characterized in triplicate. Collagen content was quantified using FIJI/ImageJ software by interactive thresholding, conversion of the image into a binary image, and direct pixel counting of the images.
Cell treatments and quantitative polymerase chain reaction microarrays
Primary female human peritoneal mesothelial (MES-F) cells were obtained from Zen-Bio and maintained in MSO-1 Mesothelial Cell Growth Medium (Zen-Bio) (32, 33) . Cell transduction was accomplished with sh-KLF11 lentivirus (MISSION shRNA lentiviral transduction SHCLNV-NM_003597, TRCN000256924; SigmaAldrich) and hexadimethrine bromide by incubation overnight at 37°C per laboratory protocol. KLF11 knockdown in MES-F cells was confirmed by western blot analysis as described (9) . Briefly, 20 mg of total protein was applied to a 10% polyacrylamide gel. After transfer and blocking, the membrane was incubated with mouse anti-KLF11 (1:500; Abcam) and b-tubulin (1:1000; Abcam) antibodies.
Cells were treated with chlorhexidine 0.001% (C9394; Sigma), estradiol 50 nM (ab145743; Cambridge), medroxyprogesterone acetate 100 nM (Q3025-00; Steraloids), or a combination with vehicle controls at 37°C for 48 hours per published doses (34) (35) (36) (37) . Total RNA from one 10-cm dish of 80% confluent peritoneal cells was extracted using the RNeasy kit (Qiagen) per protocol. Then, 2 mg total RNA was used for complementary DNA synthesis using Oligo-dT primer in a SuperScript III first-strand synthesis system (Invitrogen) per protocol. The fibrosis RT 2 profiler PCR array (PAMM-120z; Qiagen) containing 84 key fibrosis genes and 5 endogenous control genes was used. The reactions were performed using the IQ-SYBR Green Supermix (Bio-Rad) per protocol in a StepOne Plus Real-Time PCR System (Applied Biosystems). Supplemental Table 1 lists the genes measured in this assay. Five endogenous genes were used for normalization: B2M, HPRT1, RPL13A, GASPH, and b-actin. The data were analyzed using the PCR Array Data Analysis Software from SABiosciences. Each experiment was repeated in triplicate three times.
Immunohistochemistry and immunofluorescence
Tissue sections were first deparaffinized and then rehydrated in xylene and a series of graded concentration ethanol solutions. Antigen retrieval was performed by heating slides in a steamer for 20 minutes in 10 mM citrate buffer (pH 6.0). Endogenous peroxide was quenched using a solution of hydrogen peroxide/ methanol solution followed by avidin/biotin blocking (Vector Laboratories) followed by a blocking solution (CAS Block; Invitrogen). This was followed by incubation with rabbit antiprogesterone receptor [1: 
Data analysis
Comparison between murine groups was performed using the Wilcoxon rank-sum test, the nonparametric equivalent to the unpaired t test, or the Kruskal-Wallis test, the nonparametric equivalent to the analysis of variance test to compare more than two groups. We had estimated that at least four animals would be required per treatment group to estimate a 30% difference in fibrosis scores. The Bonferroni method of multiple comparisons (t tests) or x 2 tests were also used as indicated by data type. All statistics were assessed using JMP Pro 10. Statistical significance was set at P # 0.05. Data are presented as mean 6 standard error of the mean except where otherwise specified.
Results
Klf11
2/2 female mice selectively developed fibrosis after induction of sterile peritonitis Loss of Klf11 regulation in Klf11 2/2 mice results in progressive intra-abdominal fibrosis as evidenced in endometriosis disease models (18) . To determine if peritoneal fibrosis was a sexually dimorphic response, we treated female and male wt and Klf11 2/2 mice with an IP sclerosing agent (chlorhexidine) using a previously published model; this experimental design enabled us to interrogate fibrotic progression in both sexes (23) . The animals were administered either IP vehicle or chlorhexidine daily for 3 weeks (n = 5 to 7 animals per group). On completion of the 3-week course, the IP fibrotic phenotype was evaluated at necropsy. None to minimal fibrosis was seen in wt males, wt females, and Klf11 2/2 males; rare adhesions, when observed in these animals were isolated, filmy, and nonobliterating ( Fig. 1A-1F ). Lack of spreading mesenteric fibrosis enabled the bowel mesentery to be splayed, and no bowel shortening was visualized (Fig. 1B, 1D , and 1F). The extent of fibrosis in each animal was objectively recorded using a well-characterized murine adhesion scoring system (18, 30) . Accordingly, mean scores were 9 6 0 in wild-type males, 9.3 6 0.9 in wild-type females, and 9 6 0 in Klf11 2/2 males administered IP chlorhexidine (Fig. 1I ). In comparison, mean scores in wt females and Klf11 2/2 males administered vehicle control were 9 6 0 and 9 6 0, respectively, which did not differ from equivalent scores in similar mice treated with chlorhexidine. Fibrotic extent and corresponding fibrosis scores were also comparable and no different among the three groups of animals irrespective of type of treatment. All animals tolerated treatment well with no treatment-related mortality or weight loss from failure to thrive. Mean 6 standard deviation weights (g) were 25.6 6 2.5, 23.4 6 1.6, and 24.2 6 3.6 in wt males, wt females, and Klf11 2/2 males treated with chlorhexidine, respectively. Animal weights in the respective control groups were similar to the treatment group (Fig. 1J) . In contrast to wt animals and Klf11 2/2 males, Klf11
female mice developed progressive fibrosis in response to IP chlorhexidine ( Fig. 1G and 1H ). The adhesions were dense and resulted in partial or complete obliteration of the peritoneal cavity. Spreading mesenteric fibrosis resulted in varying degrees of apparent shortening of the intestines, which could also not be unraveled and splayed. One mouse developed ileus due to bowel adhesions and was consequently killed after only 2 weeks of sclerosant therapy. Mean fibrosis scores in Klf11 2/2 female mice were 47 6 18 ( Fig. 1I) . Aside from the single mouse that developed ileus, all others maintained their body weight throughout the treatment phase; mean animal weight in this group at necropsy was 23.4 6 1.6 g (Fig. 1J ). The Kruskal-Wallis test was used to compare more than two groups. Compared with all other groups, the fibrosis score in Klf11 2/2 females was significantly increased (P = 0.0002). Animal body weight did not significantly differ between groups (P = 0.2885). Fig. 2A, 2G , and 2J). Adhesions, when observed were isolated, thin, and filmy and did not obliterate peritoneal anatomy (Fig. 2B,  2H , and 2K). In addition, lack of mesenteric scarring caused no apparent bowel shortening in these animals (Fig. 2C, 2I , and 2L). Mean fibrosis scores in all three groups were comparable at 9 6 0.8, 9.2 6 0.8, 9.6 6 1.3 in wt ovx+, wt sham, and Klf11 2/2 ovx+ mice (Fig. 2M ). Animal weights also did not differ across the groups with mean 6 standard deviation weight (g) of 22.1 6 2.2, 19.8 6 0.6, and 22.0 6 1.7 in wt ovx+, wt ovx2, and Klf11 2/2 ovx+ mice, respectively ( Fig. 2N ). In contrast, Klf11 2/2 mice that underwent sham surgery retained both ovaries in situ and displayed phenotypic progression ( Fig. 2D-2F ; box) in response to treatment with chlorhexidine ( Fig. 2E and 2F ) but not vehicle (Fig. 2D ). Fibrotic progression in these animals was similar in extent to that observed in Klf11 2/2 female mice treated with chlorhexidine ( Fig. 1) . Two mice from the sham surgery + chlorhexidine group had to be killed early (2 weeks) due to evidence of discomfort. All mice in this group developed dense adhesions, obliteration of the peritoneal cavity, and bowel shortening ( Fig. 2E and 2F , arrows). The mean fibrosis score in these Klf11 2/2 ovx2 mice was 47 6 9, P , 0.0001 (Fig. 2M) . Despite early termination of treatment in two animals, mean body weight in this group was 21.5 6 3.4 g, which did not statistically differ from the other groups; P = 0.99 (Fig. 2N) .
Ovariectomy prevented fibrosis in Klf11
Progesterone was the sex steroid mediator of peritoneal fibrotic progression Having determined that ovariectomy and corresponding loss of sex steroid exposure abrogated fibrotic progression, we next evaluated whether estradiol and/or progesterone mediated this pathological phenotype. Accordingly, 8-weekold wt or Klf11 2/2 mice underwent ovariectomy. One week after ovariectomy, the mice were administered estradiol, progesterone, or vehicle by daily subcutaneous injection. The mice were also simultaneously administered IP chlorhexidine or ethanol vehicle. All treatments were continued for 3 weeks, following which phenotypic progression was evaluated at necropsy (n = 5 animals/group). Wt animals typically did not develop scarring in response to chlorhexidine; accordingly, the scores were low Sexual dimorphism in intra-abdominal adhesion formation and fibrosis was assessed by induction of sterile peritoneal inflammation using IP vehicle or chlorhexidine (shown) in wt and Klf11 2/2 male and female mice (n = 5 to 7 animals per group). Fibrotic progression was assessed morphometrically and scored using a modified fibrotic system. In this experimental model, peritoneal fibrosis most commonly affects the intestinal mesentery and obliterates tissue planes, resulting in apparent bowel shortening. Chlorhexidine therapy did not result in any obvious fibrosis in (A) wt male, (C) wt female, or (E) Klf11 2/2 male animals. Lack of spreading fibrosis in these animals also did not involve the mesentery; as a result, there was no apparent shortening of the bowel, and the intestines could be readily exteriorized and unraveled (B, D, and F in wt male, wt female, and Klf11 2/2 male animals, respectively). In contrast, (G) generalized fibrosis in Klf11 2/2 females precluded anatomic visualization and separation of intra-abdominal viscera; (H) mesenteric fibrosis caused apparent bowel shortening and inability to exteriorize and unravel the intestines (arrows). (I) Average fibrosis score for each genotype 6 standard error of the mean is represented as a bar in the graph. The average fibrosis score in Klf11 2/2 females (47 6 8) was significantly higher than the other three groups using the Kruskal-Wallis test, *P = 0.002 for indicated comparison; representative findings shown. (J) Average body weight in grams 6 standard error of the mean is represented as a bar in the graph; all animal groups had similar body weights, P = 0.2885. and comparable in wt ovariectomized mice treated with either subcutaneous estradiol or vehicle ( Fig. 3A and 3C ). Lack of spreading peritoneal and mesenteric scarring did not cause apparent shortening of the bowel and enabled intestinal unraveling ( Fig. 3B and 3D ). Fibrosis scores in both groups (treatment and control) of wt, ovariectomized mice were thus low, constant, and unchanged (Fig. 3M , white bars; mean score 9 6 0).
In Klf11 2/2 mice, scarring was minimal after ovariectomy (Fig. 2) . The extent of scarring remained unchanged in ovariectomized animals treated with either vehicle or estradiol ( Fig. 3G and 3I ). As in wt mice, lack of spreading peritoneal and mesenteric scarring in estradioltreated Klf11 2/2 mice did not cause apparent shortening of the bowel and enabled intestinal unraveling ( Fig. 3H  and 3J ). Fibrosis scores accordingly reflected absent or minimal scarring in ovariectomized Klf11 2/2 animals administered IP chlorhexidine irrespective of whether the animals were also treated with vehicle or estradiol (Fig. 3M, black bars) . Fibrosis scores among ovariectomized wt and Klf11 2/2 animals were thus comparable in vehicle-or estradiol-treated mice (Fig. 3M , vehicle and E2). At necropsy, enlarged and dilated uteri were evident in all estrogen-exposed mice. No additional fibrosis was thus seen after estradiol replacement ( Fig. 3I and  3J ). Klf11 2/2 ovariectomized mice had a mean fibrosis score of 9 6 0. The phenotype in chlorhexidinetreated, ovariectomized Klf11 2/2 mice (Fig. 2) remained unaffected despite vehicle or estradiol treatment (P = 0.37, fibrosis score comparison).
In contrast, chlorhexidine-treated, ovariectomized Klf11 2/2 (but not wt) mice developed progressive fibrosis in response to progesterone supplementation (Fig. 3E, 3F , 3K, and 3L). These Klf11 2/2 animals expressed progesterone receptor in the peritoneal cells (Supplemental Fig. 2A) . In contrast to progesterone-treated wt ovariectomized controls (Fig. 3F) , spreading peritoneal and mesenteric fibrosis caused apparent bowel shortening, intestinal entrapment in scar, and consequent matting in ovariectomized, progesterone-supplemented Klf11 2/2 mice (Fig. 3L) . These had fibrosis scores of 37 6 9, which significantly differed from those in vehicle-or estradioltreated Klf11 2/2 (and wt) animals ( Fig. 3M , P = 0.0069).
Moreover, the score was comparable to chlorhexidinetreated, nonovariectomized Klf11 2/2 animals ( Fig. 1 ;
Peritoneal fibrosis was a sexually dimorphic phenotype Our data implicated progesterone as the sex steroid associated with fibrotic progression in Klf11 2/2 female mice (Fig. 3) . As chlorhexidine-injected male mice remained resistant to fibrosis, we hypothesized that like estradiol, testosterone was potentially protective from scarring. To further evaluate the role of testosterone in this experimental model system, we supplemented chlorhexidine-treated, ovariectomized Klf11 2/2 females with dihydrotestosterone (Fig. 4) . No fibrosis was seen after dihydrotestosterone replacement in wt or Klf11 2/2 ovariectomized mice ( Fig. 4A-4D ). Lack of peritoneal/mesenteric scarring did not result in either intestinal shortening or matting ( Fig. 4B  and 4D ). Mean fibrosis scores in these animals were 9.2 6 1 and 10 6 1.7, respectively; n = 5 animals/group (Fig. 4E ).
Antiprogestin therapy abrogated fibrotic progression in Klf11 2/2 female mice We have thus far shown that fibrotic progression selectively occurred in progesterone-exposed Klf11 2/2 mice. Moreover, phenotypic fidelity was retained irrespective of the mode of progesterone exposure-whether physiological in nonovariectomized animals ( Fig. 1) or pharmacological in ovariectomized, progesteronesupplemented animals (Fig. 3) . To further confirm the role of progesterone in fibrotic progression, we treated nonovariectomized mice with two different progesterone antagonists and induced sterile peritonitis using chlorhexidine. Accordingly, wt and Klf11 2/2 mice were treated with mifepristone, ulipristal, or vehicle controls and chlorhexidine injections; n = 7 mice/group. As expected, Klf11 2/2 females in the control group developed IP adhesions and bowel shortening with a mean fibrosis score of 34 6 8 ( Fig. 5A , 5B, and 5G). In contrast, female Klf11 2/2 mice treated with mifepristone (RU486) and chlorhexidine injections had no significant IP fibrosis at necropsy (mean fibrosis score of 9 6 0; P = 0.0092 compared with control) (Fig. 5C, 5D , and 5G). All mice had an enlarged uterus consistent with the expected treatment effect from the mifepristone. Female Klf11
mice treated with ulipristal and chlorhexidine injections also had none or minimal fibrosis at necropsy (mean fibrosis score of 9.8 6 1.8; P = 0.0063 compared with control) (Fig. 5E, 5F , and 5G). Ulipristal-treated mice were also noted to have enlarged uteri consistent with treatment effect, although less so in extent compared with mifepristone.
Endogenous testosterone prevented progesterone-mediated fibrotic progression in Klf11 2/2 male mice To determine if endogenous testosterone was sufficient to prevent pharmacological progesterone-induced fibrosis, we treated noncastrated Klf11 2/2 mice with progesterone and chlorhexidine for induction of sterile peritonitis. Progesterone-treated Klf11 2/2 male mice had minimal fibrosis that was similar in extent to control male Klf11 2/2 mice given sesame oil injections and chlorhexidine injections ( Fig. 6A and 6C ). In these mice, lack of mesenteric scarring preserved intestinal anatomy (Fig. 6B) . To determine if endogenous testosterone prevented fibrosis, we performed bilateral orchiectomy and treated the castrated males with either vehicle or progesterone. Orchiectomized Klf11 2/2 male mice given progesterone and chlorhexidine developed peritoneal fibrosis with mesenteric scarring as well as apparent bowel shortening (Fig. 6D) ; these animals had a mean fibrosis score of 51 6 4. In contrast, orchiectomized mice treated with sesame oil and chlorhexidine had a mean fibrosis score of 9 6 0; P = 0.12. In addition, mean fibrosis scores were 12 6 3 in nonorchiectomized Klf11 2/2 males administered progesterone and chlorhexidine and 9 6 0.5 in nonorchiectomized Klf11 2/2 males administered sesame oil and chlorhexidine, respectively (Fig. 6E) .
Progesterone antagonist treatment increased peritoneal collagen content in Klf11 2/2 female mice We have previously shown that loss of Klf11 resulted in activation of Col1a1 and fibrosis in endometrial stromal cells using a mouse endometriosis model. The current experimental design, however, differs from that used previously by exclusively assessing the peritoneal fibrotic response in the absence of surgically induced endometriosis. Given disparate fibrotic progression under differential sex steroid exposure in our current model, we determined if there were also corresponding differences in peritoneal collagen expression. To do this, we sampled parietal peritoneum that was exposed to chlorhexidine but not phenotypically scarred. Increased collagen deposits (blue stain: Mason trichrome; arrows) were observed in Klf11 2/2 mice treated with IP chlorhexidine and injected with vehicle (oil) in contrast to similarly treated wt controls ( Fig. 7A and 7C , peritoneal cavity). Ovariectomy did not alter the extent of peritoneal collagen deposition in wt animals, although this was significantly diminished in Klf11 2/2 mice ( Fig. 7B and   7D ). The extent of collagen deposition, however, was significantly increased in ovariectomized Klf11 2/2 animals treated with progesterone; in contrast, deposition was further diminished in animals treated with estradiol ( Fig. 7E and 7F ). Quantification of Masson trichrome staining for collagen revealed that the intensity of blue stain per 100,000 pixels was significantly higher in Klf11 2/2 mice that underwent sham surgery as well as those that were ovariectomized and supplemented with Lack of spreading fibrosis in these animals also did not involve the mesentery; as a result, there was no apparent shortening of the bowel and the intestines could be readily exteriorized and unraveled. (E) Fibrosis scores in animals of both genotypes (9 6 0 and 9 6 0; vehicle-treated wt and Klf11 2/2 ; 9.2 6 1 and 10 6 1.7: DHT-treated wt and Klf11 2/2 ) were comparable and also did not differ between treatment and vehicle control groups. n = 5 animals/group; representative findings shown.
progesterone ( Fig. 7J ; P , 0.05 for indicated comparisons). In addition, collagen deposition was significantly lower in nonovariectomized Klf11 2/2 females treated with ulipristal compared with vehicle-treated controls, P = 0.002 ( Fig. 7H and 7I) . We also observed a trend toward diminished peritoneal collagen deposition in mifepristone-treated nonovariectomized Klf11 2/2 mice, although this was not statistically significant compared with controls, P = 0.069 ( Fig. 7H and 7J ).
Progesterone and KLF11 drove similar profibrotic gene expression profiles in primary human peritoneal cells To determine if profibrotic mechanisms are activated in human peritoneal cells in response to loss of KLF11, we treated a primary female peritoneal mesothelial cell line (MES-F) with Klf11 short hairpin RNA (shRNA), chlorhexidine, and vehicle, estradiol, or medroxyprogesterone acetate. The experimental design thus replicated in vivo animal treatments in vitro on human peritoneal cells. We initially determined that KLF11/ KLF11 expression was diminished 85% in cells transduced with KLF11 shRNA compared with cells transduced with a scrambled control (Fig. 8A , upper and lower panels; P , 0.05). We next evaluated the expression of profibrotic genes and signaling pathways using a specific polymerase chain reaction array in these cells in response to additional treatment with sex steroids or vehicle control. Compared with cells treated with vehicle, several profibrotic genes were upregulated in cells treated with KLF11 shRNA and progesterone in contrast to those treated with KLF11 shRNA and estradiol (Fig. 8B-D) . We have previously shown that transcriptional dysregulation of the chief scar tissue protein COL1A1 from loss of KLF11 expression in endometrial stromal cells results in altered expression levels (18) . We further observed that Col1a1 expression levels directly correlated with the extent of fibrosis. To determine if this specific mechanism was also altered in human peritoneal cells in response to diminished KLF11 expression and differential female sex steroid exposure, we specifically evaluated COL1A1 exposure in addition to the profibrotic signaling polymerase chain reaction array (Fig. 8E) . COL1A1 messenger RNA expression was significantly increased (1.4-fold) only in human peritoneal cells with diminished Figure 5 . Progesterone antagonist therapy prevented fibrotic progression in Klf11 2/2 mice. Nonovariectomized Klf11 2/2 mice treated with vehicle developed progressive fibrosis (A, Fig. 1G ), resulting in mesenteric scarring and apparent shortening of the intestines that could not be unraveled for anatomic display (B, Fig. 1H ). In contrast, fibrotic progression was significantly diminished in animals administered either a (C) progesterone antagonist RU486 or (E) ulipristal, a selective progesterone receptor modulator. In both RU486-and ulipristal-administered animals, lack of spreading fibrosis Figure 5 . (Continued). in these animals also did not involve the mesentery; as a result, there was no apparent shortening of the bowel and the intestines could be readily exteriorized and unraveled (D and F, respectively). (G) Compared with vehicle-treated controls, the fibrosis score in both RU486-and ulipristal-treated animals was significantly lower. *P = 0.0092 (RU486 compared with vehicle) and P = 0.0063 (ulipristal compared with vehicle); representative findings shown, n = 7 animals per group. Ctrl, control; Ulipr., ulipristal.
KLF11 expression that were further exposed to progesterone ( Fig. 8E ; P , 0.05). In contrast, when these cells were exposed to estradiol, COL1A1 expression was diminished by 40% ( Fig. 8E ; P , 0.05). There was no difference in COL1A1 messenger RNA expression in control cells treated with scrambled shRNA. Progesterone receptor was also expressed in the nuclei and cytoplasm of this cell line (Supplemental Fig. 1B) .
Discussion
Fibrosis-related morbidity from chronic disease constitutes a substantial health problem. Although differing in initial etiology and pathogenesis, a wide spectrum of medical conditions such as collagen vascular diseases, chronic pain syndromes, endometriosis, and surgical healing evolve into chronic states associated with scarring and pain. Scarring also complicates chronic disease in individual organs and systems such as the liver and lungs (4) (5) (6) (7) (8) 10) . In addition to pain, fibrous replacement of parenchyma in these sites results in organ dysfunction. Current medical treatments are unable to adequately address this condition, resulting in high medical and social costs (38) . Recent studies have implicated increased incidence of these conditions in females. In fact, endometriosis is an almost exclusively female disease that affects 10% of reproductive age women with chronic sequelae in a substantial proportion. We therefore investigated if fibrosis has a sexually dimorphic predilection and if such distinction has therapeutic relevance.
In previous studies, we observed progressive fibrosis in a Klf11 2/2 female animal endometriosis model (18) .
This model is of further interest as fibrosis was the outcome of dysregulated scar tissue collagen deposition, which could be specifically reversed by directed epigenetic inhibitor therapy (22, 30) . Endometriosis in these nonmenstruating animals is surgically induced via suture of uterine endometrium onto parietal peritoneum (39) (40) (41) (42) . Such an experimental design, however, precluded comparative investigation of sex-specific fibrotic predilection. We therefore used a well-characterized peritoneal sclerosis disease model in these experiments (23) . Adult male and female wt and Klf11 2/2 mice were administered IP chlorhexidine, an antiseptic detergent to induce sterile, chemical peritonitis. Fibrosis was only observed in female Klf11 2/2 animals but not in wt or Klf11 2/2 male animals, which suggested that female sex and loss of Klf11 signaling were both necessary for fibrotic progression. Given the endocrine differences in males and females, we next addressed the role of female sex steroids in informing the fibrotic phenotype after bilateral ovariectomy resulting in in vivo sex steroid depletion. Scarring was abrogated by bilateral ovariectomy, which further implicated the etiological role of female sex steroids in fibrosis. In subsequent experiments, we showed that progesterone but not estradiol was associated with progressive scarring; moreover, the latter was potentially protective with less fibrosis compared with controls. We further observed that fibrotic extent in these animals was associated with differential expression of profibrotic genes and signaling pathways. Our studies also highlighted other critical findings related to the role of sex steroids and progressive fibrosis. Noncastrated males did not develop fibrosis after pharmacological progesterone supplementation. In contrast, castrated Klf11 2/2 males, like ovariectomized Klf11
females, developed peritoneal scarring in response to progesterone. Based on these findings, we speculate that in noncastrated males, either physiological testosterone was sufficient to overcome any profibrotic effects of progesterone or other independent, male sex-specific, antifibrotic mechanisms (that our study design did not evaluate) may have variably contributed to lack of fibrosis. However, lack of fibrosis in dihydrotestosterone-supplemented ovariectomized Klf11 2/2 females treated with chlorhexidine in contrast to animals treated with progesterone suggests that testosterone is antifibrotic and that physiological or pharmacologic testosterone supplementation may overcome any profibrotic progesterone effect. Fibrotic progression was evident in Klf11 2/2 female mice exposed to physiological or pharmacological progesterone. We have previously shown that fibrosis in the animal endometriosis model is predominantly lesion driven via abnormal profibrotic gene expression and resultant anomalous differentiation of ectopic endometrial stromal cells (22) . Our findings in the current study, however, suggest that peritoneal mesothelium, which serves as host tissue for endometriotic implants, also has a role in fibrotic progression. Given that Klf11 2/2 female animals that underwent sham surgery (peritoneal incision only) did not develop scarring suggests that genotypespecific scarring developed in response to threshold injury-which was use of chlorhexidine or surgical implantation of endometrial tissue. In response to threshold injury, however, animals with dysregulation of Klf11/ epigenetic mechanisms and progesterone exposure have a predilection for progressive fibrosis. Although KLF11/ collagen dysregulation is associated with fibrotic progression, the mechanistic initiation of this mechanism appears to be heterogeneous. We have previously found that loss of KLF11 was sufficient to activate COL1A1 expression in endometrial stromal cells; moreover, this was the dominant mechanism for endometriosis lesiondriven fibrosis (18, 22, 30) . In these studies, we found that dysregulation of COL1A1 expression in human peritoneal cells required progesterone exposure as well as mitigated KLF11 repression. Although differences in experimental design, extent of KLF11 repression, and cell-type response likely contribute to these observations, these findings nevertheless have implications in nonendometriotic fibrosis. In addition, the lesion extrinsic peritoneal response to fibrotic progression in endometriosis may depend on the prevalent sex steroid milieu, which for us is an area of further mechanistic investigation. We have previously shown that KLF11 is selectively downregulated in human endometriosis lesions compared with corresponding eutopic endometrium (18) . One mechanism for diminished KLF11 expression in human disease may be from tissue-specific promoter methylation, as shown in ovarian cancer (16) . KLF11/ epigenetic dysregulation is also associated with other human diseases such as leiomyomata and diabetes (15, 17, 43, 44) . Others have previously shown that KLF11 is a progesterone target with tumor-suppressive effects (17) . Our data suggest that estradiol and testosterone mitigate, whereas progesterone potentiates, progressive fibrosis driven by loss of Klf11 function, resulting in dysregulated scar tissue collagen expression. Furthermore, this mechanism has translational relevance as it can be arrested by targeted therapy (22, 30) . We have previously shown that fibrosis driven by lesion-intrinsic mechanisms is responsive to an epigenetic histone acetyl transferase inhibitor (22) . Moreover, when coadministered, histone acetyl transferase inhibitor and a transforming growth factor-b receptor inhibitor acted synergistically to diminish scarring (30) . In these studies, we found that threshold stimuli induced comparable fibrosis, which was exclusively driven by peritoneal mesothelial cells; in endometriosis, this tissue was extrinsic to the lesion. Nevertheless, scarring from both intrinsic and extrinsic mechanisms was associated with loss of Klf11/epigenetic regulation and activation of type 1 collagen. We found here that lesion extrinsic mechanisms are sexually dimorphic, facilitated by progesterone, and inhibited by inhibitors of progesterone signaling.
Although estrogen is extensively implicated in the progression of human endometriosis, our findings suggest that estradiol was protective at least in the peritoneal reaction to potential fibro-inflammatory stimuli such as exposure to sclerosant and potentially ectopic endometrial implantation (45) (46) (47) (48) . Endometriosis is a highly heterogeneous disease of diverse etiology and pathogenesis; the disease remains recalcitrant to current therapeutic modalities as they are nonindividualized and empiric. Endometriosis is hypothesized to initiate following retrograde menstruation of endometrial tissue into the peritoneal cavity. Endometrial cells in the menstrual phase are progesterone primed; it is therefore possible for progesterone to have a role in endometriotic establishment and fibrosis. Furthermore, many therapies for endometriosis are progesterone dominant or abrogate sex steroid action altogether (45) . Such treatments could potentially aggravate scarring, disease chronicity, and recalcitrance. Select patients may in fact potentially benefit from estradiol, antiprogesterone, epigenetic inhibitor, or transforming growth factor-b receptor inhibitor treatment based on concordant evaluation of disease phenotype and determination of their individualized dysregulated gene expression pattern. We are currently investigating the role of estradiol and progesterone administration in our animal endometriosis models to further delineate the specific role of these steroids on disease-associated fibrosis.
Other groups have investigated the utilization of selective progesterone receptor modulators in the management of endometriosis-associated pain. Clinical data in endometriosis reveal that pain and fibrotic progression are not always correlated. This observation may be further nuanced based on variations in pain perception and tolerance by different individuals. Moreover, fibrosis impedes end-organ function to cause an array of symptoms besides pain that affect lifestyle and may remain unaddressed with a purely nociceptive focus on therapy. A primary treatment goal in endometriosis is pain mitigation rather than reversal of pathophysiology; the impact of any therapeutic intervention would be determined subjectively for pain and require objective documentation for the latter. Novel therapeutic approaches that address both would prognosticate lasting cures. Mifepristone treatment reduced endometriosis symptoms in human and rat studies, whereas asoprisnil specifically and significantly reduced nonmenstrual pelvic pain in humans (49) (50) (51) (52) . Ulipristal, also evaluated here, was associated with diminished Cox2 expression in rats, whereas tanaproget decreased matrix metalloproteinase expression and lesion number in human and animal model studies (53, 54) .
The findings of this study were based on a generalized fibrosis model and may thus have broader implications beyond endometriosis such as postoperative adhesion formation, encapsulating peritoneal sclerosis, pulmonary hypertension, and other fibrotic diseases that affect both sexes. Studies have shown an increased incidence of postoperative adhesion-induced intestinal obstruction as well as encapsulating peritoneal sclerosis in premenopausal females (9, 55, 56) . Outside the abdomen, pulmonary hypertension also has female predominance (57). Progesterone and/or KLF11 may have a role in the sexual dimorphism that underlies these diseases.
Besides sex hormone variance, sexual dimorphism can also be explained by selective expression of genes located on the Y chromosome. The Y chromosome is the smallest and most variable of the chromosome, with over 200 genes. Although our data point to a strong association with differential sex steroid activity, Y-chromosomal gene expression remains an alternative plausibility that may be cooperative, necessary, or even sufficient for these findings. Although we plan to comprehensively investigate this alternative hypothesis by global RNA sequencing of tissues in ongoing experiments, it is critical to note that sex hormone differences noted here were sufficient to induce drastic phenotypic differences as well as were amenable to targeted inhibitor therapy.
Although these studies indicate that progressive scarring in chronic disease is a sexually dimorphic phenotype, we are currently further mechanistically investigating the interplay of underlying pro-and antifibrotic signaling pathways that are differentially recruited by the sex steroids. We are also evaluating the repression of Klf11 and its potential regulation by progesterone. Our findings have translational relevance and, to the best of our knowledge, created novel approaches for individualized diagnosis and medical treatment of chronic disease-associated scarring that may offer new hope in mechanistic understanding and therapy.
